[6-K] Novo-Nordisk A/S Current Report (Foreign Issuer)
Form 6-K insider transaction report
On 8 Aug 2025, Novo Nordisk A/S (NVO) disclosed a managerial transaction under EU Market Abuse Regulation Article 19. Executive Vice President Ludovic Helfgott sold 28,710 class B shares (ISIN DK0062498333) on Nasdaq Copenhagen on 7 Aug 2025 at DKK 295.00 per share, generating gross proceeds of DKK 8,469,450.
The filing contains no financial results, strategic updates or additional insider dealings; it solely records this single transaction. Accordingly, investors receive limited insight into current operating performance, and the trade’s materiality is modest relative to Novo Nordisk’s market capitalisation.
Rapporto sulle transazioni interne Modulo 6-K
In data 8 agosto 2025, Novo Nordisk A/S (NVO) ha comunicato una transazione manageriale ai sensi dell'Articolo 19 del Regolamento UE sul Market Abuse. Il Vice Presidente Esecutivo Ludovic Helfgott ha venduto 28.710 azioni di classe B (ISIN DK0062498333) al Nasdaq Copenhagen il 7 agosto 2025 al prezzo di 295,00 DKK per azione, realizzando un ricavo lordo di 8.469.450 DKK.
La comunicazione non include risultati finanziari, aggiornamenti strategici né altre operazioni interne; registra esclusivamente questa singola transazione. Di conseguenza, gli investitori ricevono informazioni limitate sulle performance operative attuali, e l'importanza dell'operazione è contenuta rispetto alla capitalizzazione di mercato di Novo Nordisk.
Informe de transacción interna Formulario 6-K
El 8 de agosto de 2025, Novo Nordisk A/S (NVO) reveló una transacción gerencial conforme al Artículo 19 del Reglamento de Abuso de Mercado de la UE. El Vicepresidente Ejecutivo Ludovic Helfgott vendió 28,710 acciones clase B (ISIN DK0062498333) en Nasdaq Copenhague el 7 de agosto de 2025 a 295,00 DKK por acción, generando ingresos brutos por 8.469.450 DKK.
El informe no contiene resultados financieros, actualizaciones estratégicas ni otras operaciones internas; únicamente registra esta transacción. Por lo tanto, los inversores obtienen una visión limitada del desempeño operativo actual y la relevancia de la operación es modesta en relación con la capitalización de mercado de Novo Nordisk.
Form 6-K 내부자 거래 보고서
2025년 8월 8일, Novo Nordisk A/S (NVO)는 EU 시장남용규제 제19조에 따른 경영진 거래를 공시했습니다. 부사장 루도빅 헬프고트는 2025년 8월 7일 나스닥 코펜하겐에서 클래스 B 주식 28,710주(ISIN DK0062498333)를 주당 295.00 DKK에 매도하여 총 8,469,450 DKK의 매출을 올렸습니다.
이 공시는 재무 실적, 전략적 업데이트 또는 추가 내부자 거래를 포함하지 않으며, 단일 거래만 기록합니다. 따라서 투자자들은 현재 운영 성과에 대한 제한된 정보를 얻으며, 거래의 중요성은 Novo Nordisk의 시가총액에 비해 미미한 수준입니다.
Rapport de transaction d’initié Formulaire 6-K
Le 8 août 2025, Novo Nordisk A/S (NVO) a divulgué une transaction de direction conformément à l’article 19 du Règlement européen sur les abus de marché. Le Vice-Président Exécutif Ludovic Helfgott a vendu 28 710 actions de classe B (ISIN DK0062498333) à la Nasdaq de Copenhague le 7 août 2025 au prix de 295,00 DKK par action, générant un produit brut de 8 469 450 DKK.
Le dépôt ne contient aucun résultat financier, mise à jour stratégique ou autre transaction d’initié ; il ne fait état que de cette unique opération. Par conséquent, les investisseurs disposent d’une vision limitée de la performance opérationnelle actuelle, et la matérialité de la transaction est modeste par rapport à la capitalisation boursière de Novo Nordisk.
Formular 6-K Insider-Transaktionsbericht
Am 8. August 2025 gab Novo Nordisk A/S (NVO) eine geschäftsführende Transaktion gemäß Artikel 19 der EU-Marktmissbrauchsverordnung bekannt. Der Executive Vice President Ludovic Helfgott verkaufte 28.710 Klasse-B-Aktien (ISIN DK0062498333) am 7. August 2025 an der Nasdaq Kopenhagen zum Preis von 295,00 DKK pro Aktie und erzielte Bruttoerlöse von 8.469.450 DKK.
Die Meldung enthält keine Finanzergebnisse, strategische Updates oder weitere Insidergeschäfte; sie dokumentiert ausschließlich diese einzelne Transaktion. Dementsprechend erhalten Investoren nur begrenzte Einblicke in die aktuelle operative Leistung, und die Bedeutung des Handels ist im Verhältnis zur Marktkapitalisierung von Novo Nordisk gering.
- None.
- Executive Vice President sold 28,710 shares worth DKK 8.47 m, a move some investors may interpret as a minor negative sentiment signal.
Insights
TL;DR: EVP sells DKK 8.5 m in shares; modest size, limited signal.
The disclosed insider sale equals roughly US$1.2 m—immaterial versus Novo Nordisk’s >US$550 bn market value. Single-executive disposals often reflect personal liquidity needs rather than outlook changes, yet repeated or larger-scale sales could signal sentiment. With no accompanying performance data or guidance, the event is neutral for valuation.
TL;DR: Routine MAR Article 19 filing; governance processes intact.
The company promptly reported the transaction, demonstrating compliance with EU disclosure rules. No amendments or multiple trades are noted, and the notification is an initial filing, suggesting procedural clarity. Governance impact is neutral; however, monitoring future insider activity remains prudent for pattern detection.
Rapporto sulle transazioni interne Modulo 6-K
In data 8 agosto 2025, Novo Nordisk A/S (NVO) ha comunicato una transazione manageriale ai sensi dell'Articolo 19 del Regolamento UE sul Market Abuse. Il Vice Presidente Esecutivo Ludovic Helfgott ha venduto 28.710 azioni di classe B (ISIN DK0062498333) al Nasdaq Copenhagen il 7 agosto 2025 al prezzo di 295,00 DKK per azione, realizzando un ricavo lordo di 8.469.450 DKK.
La comunicazione non include risultati finanziari, aggiornamenti strategici né altre operazioni interne; registra esclusivamente questa singola transazione. Di conseguenza, gli investitori ricevono informazioni limitate sulle performance operative attuali, e l'importanza dell'operazione è contenuta rispetto alla capitalizzazione di mercato di Novo Nordisk.
Informe de transacción interna Formulario 6-K
El 8 de agosto de 2025, Novo Nordisk A/S (NVO) reveló una transacción gerencial conforme al Artículo 19 del Reglamento de Abuso de Mercado de la UE. El Vicepresidente Ejecutivo Ludovic Helfgott vendió 28,710 acciones clase B (ISIN DK0062498333) en Nasdaq Copenhague el 7 de agosto de 2025 a 295,00 DKK por acción, generando ingresos brutos por 8.469.450 DKK.
El informe no contiene resultados financieros, actualizaciones estratégicas ni otras operaciones internas; únicamente registra esta transacción. Por lo tanto, los inversores obtienen una visión limitada del desempeño operativo actual y la relevancia de la operación es modesta en relación con la capitalización de mercado de Novo Nordisk.
Form 6-K 내부자 거래 보고서
2025년 8월 8일, Novo Nordisk A/S (NVO)는 EU 시장남용규제 제19조에 따른 경영진 거래를 공시했습니다. 부사장 루도빅 헬프고트는 2025년 8월 7일 나스닥 코펜하겐에서 클래스 B 주식 28,710주(ISIN DK0062498333)를 주당 295.00 DKK에 매도하여 총 8,469,450 DKK의 매출을 올렸습니다.
이 공시는 재무 실적, 전략적 업데이트 또는 추가 내부자 거래를 포함하지 않으며, 단일 거래만 기록합니다. 따라서 투자자들은 현재 운영 성과에 대한 제한된 정보를 얻으며, 거래의 중요성은 Novo Nordisk의 시가총액에 비해 미미한 수준입니다.
Rapport de transaction d’initié Formulaire 6-K
Le 8 août 2025, Novo Nordisk A/S (NVO) a divulgué une transaction de direction conformément à l’article 19 du Règlement européen sur les abus de marché. Le Vice-Président Exécutif Ludovic Helfgott a vendu 28 710 actions de classe B (ISIN DK0062498333) à la Nasdaq de Copenhague le 7 août 2025 au prix de 295,00 DKK par action, générant un produit brut de 8 469 450 DKK.
Le dépôt ne contient aucun résultat financier, mise à jour stratégique ou autre transaction d’initié ; il ne fait état que de cette unique opération. Par conséquent, les investisseurs disposent d’une vision limitée de la performance opérationnelle actuelle, et la matérialité de la transaction est modeste par rapport à la capitalisation boursière de Novo Nordisk.
Formular 6-K Insider-Transaktionsbericht
Am 8. August 2025 gab Novo Nordisk A/S (NVO) eine geschäftsführende Transaktion gemäß Artikel 19 der EU-Marktmissbrauchsverordnung bekannt. Der Executive Vice President Ludovic Helfgott verkaufte 28.710 Klasse-B-Aktien (ISIN DK0062498333) am 7. August 2025 an der Nasdaq Kopenhagen zum Preis von 295,00 DKK pro Aktie und erzielte Bruttoerlöse von 8.469.450 DKK.
Die Meldung enthält keine Finanzergebnisse, strategische Updates oder weitere Insidergeschäfte; sie dokumentiert ausschließlich diese einzelne Transaktion. Dementsprechend erhalten Investoren nur begrenzte Einblicke in die aktuelle operative Leistung, und die Bedeutung des Handels ist im Verhältnis zur Marktkapitalisierung von Novo Nordisk gering.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 8, 2025
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Page 2 of 3
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) |
Price(s) and volume(s) |
||||
| Price(s) | Volume(s) | ||||
| DKK 295.00 | 28,710 | ||||
| d) |
Aggregated information
|
28,710 shares DKK 8,469,450.00 |
|||
| e) | Date of the transaction | 2025-08-07 | |||
| f) | Place of the transaction | Nasdaq Copenhagen |
|||
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Page 3 of 3
Contacts for further information
| Media: | |
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com |
|
Max Ung +45 3077 6414 mxun@novonordisk.com |
Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
|
Alex Bruce +45 3444 2613 axeu@novonordisk.com |
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 22/ 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: August 8, 2025 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |
FAQ
How many Novo Nordisk (NVO) shares did EVP Ludovic Helfgott sell?
What was the sale price per share for the insider transaction at Novo Nordisk?
When did the Novo Nordisk insider transaction occur?
What is the total value of the shares sold by the Novo Nordisk executive?
Does the Form 6-K include any earnings or guidance updates?
